Nuvation Bio (NUVB) to Release Quarterly Earnings on Thursday

Nuvation Bio (NYSE:NUVB) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Nuvation Bio to post earnings of ($0.14) per share for the quarter.

Nuvation Bio Stock Down 0.3 %

NUVB opened at $1.82 on Wednesday. The firm has a market cap of $610.87 million, a P/E ratio of -0.84 and a beta of 1.45. Nuvation Bio has a 52 week low of $1.67 and a 52 week high of $4.16. The business’s fifty day simple moving average is $2.46 and its 200 day simple moving average is $2.60.

Analyst Ratings Changes

A number of research firms recently commented on NUVB. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a research note on Monday. HC Wainwright raised their price target on Nuvation Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $8.20.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.